Chronic obstructive pulmonary disease: A concise review

Medical Clinics of North America

Volumn 95, Issue 6, 2011, Pages 1125-1141

  Balkissoon, Ron ^a   Lommatzsch, Steve ^a   Carolan, Brendan ^a   Make, Barry ^a  

^a DEPARTMENT OF MEDICINE   (United States)

Author keywords

Chronic bronchitis; Chronic obstructive pulmonary disease; Emphysema; Guidelines

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; PHOSPHODIESTERASE IV INHIBITOR; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

BLADDER OBSTRUCTION; CATARACT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSED ANGLE GLAUCOMA; HUMAN; LUNG RESECTION; LUNG TRANSPLANTATION; OROPHARYNX CANDIDIASIS; OSTEOPENIA; OXYGEN THERAPY; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PULMONARY REHABILITATION; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN BRUISING; SMOKING CESSATION; SPIROMETRY; VOICE CHANGE;

ALGORITHMS; ANTI-INFLAMMATORY AGENTS; BRONCHODILATOR AGENTS; COMORBIDITY; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUNG TRANSPLANTATION; PNEUMONECTOMY; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPIROMETRY; TREATMENT OUTCOME;

EID: 82455219243     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2011.08.009     Document Type: Review

References (94)

1. Miniño A.M., Xu J., Kochanck K.D. Preliminary data for 2008. Natl Vital Stat Rep 2010, 59(7).
2. National Heart Lung and Blood Institute Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases 2009, National Heart, Lung, and Blood Institute, Bethesda (MD).
3. Gross N.J. What is this thing called love?-or, defining asthma. Am Rev Respir Dis 1980, 121(2):203-204.
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management and Prevention of COPD. GOLD; 2010. Available at: Accessed August 27, 2011. http://www.goldcopd.org/.
5. Wright D.T., Cohn L.A., Li H., et al. Interactions of oxygen radicals with airway epithelium. Environ Health Perspect 1994, 102(Suppl 10):85-90.
6. Blanc P.D., Iribarren C., Trupin L., et al. Occupational exposures and the risk of COPD: dusty trades revisited. Thorax 2009, 64(1):6-12.
7. Po J.Y., FitzGerald J.M., Carlsten C. Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis. Thorax 2011, 66(3):232-239.
8. Lee M.H., Hancox R.J. Effects of smoking cannabis on lung function. Expert Rev Respir Med 2011, 5(4):537-547.
9. Ko F.W., Hui D.S. Outdoor air pollution: impact on chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2009, 15(2):150-157.
10. Nakamura H. Genetics of COPD. Allergol Int 2011, 60(3):253-258.
11. Pillai D.R., Shahinas D., Buzina A., et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 2009, 10:642.
12. Han M.K. Update in chronic obstructive pulmonary disease in 2010. Am J Respir Crit Care Med 2011, 183(10):1311-1315.
13. Pillai S.G., Ge D., Zhu G., et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 2009, 5(3):e1000421.
14. Sinderby C., Spahija J., Beck J. Changes in respiratory effort sensation over time are linked to the frequency content of diaphragm electrical activity. Am J Respir Crit Care Med 2001, 163(4):905-910.
15. Seibold M.A., Schwartz D.A. The lung: the natural boundary between nature and nurture. Annu Rev Physiol 2011, 73:457-478.
16. Regan E.A., Hokanson J.E., Murphy J.R., et al. Genetic epidemiology of COPD (COPDGene) study design. COPD 2010, 7(1):32-43.
17. Guerra S. Overlap of asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005, 11(1):7-13.
18. Camp P.G., O'Donnell D.E., Postma D.S. Chronic obstructive pulmonary disease in men and women: myths and reality. Proc Am Thorac Soc 2009, 6(6):535-538.
19. Sin D.D., Cohen S.B., Day A., et al. Understanding the biological differences in susceptibility to chronic obstructive pulmonary disease between men and women. Proc Am Thorac Soc 2007, 4(8):671-674.
20. Tam A., Morrish D., Wadsworth S., et al. The role of female hormones on lung function in chronic lung diseases. BMC Womens Health 2011, 11:24.
21. Spurzem J.R., Rennard S.I. Pathogenesis of COPD. Semin Respir Crit Care Med 2005, 26(2):142-153.
22. Hogg J.C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(26):2645-2653.
23. Kirkham P., Rahman I. Oxidative stress in asthma and COPD: antioxidants as a therapeutic strategy. Pharmacol Ther 2006, 111(2):476-494.
24. Gosselink J.V., Hayashi S., Elliott W.M., et al. Differential expression of tissue repair genes in the pathogenesis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 181(12):1329-1335.
25. Vogelmeier C.F., Wouters E.F. Treating the systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011, 8(4):376-379.
26. Lee S.D., Ju G., Choi J.A., et al. The association of oxidative stress with central obesity in obstructive sleep apnea. Sleep Breath 2011, [Epub ahead of print].
27. Buist A.S., Nagy J.M. Relationship between smoking and the single breath nitrogen washout. Scand J Respir Dis Suppl 1976, 95:108-116.
28. Lee R., McNicholas W.T. Obstructive sleep apnea in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 2011, 17(2):79-83.
29. Seemungal T.A., Donaldson G.C., Paul E.A., et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(5 Pt 1):1418-1422.
30. Buist A.S., Sexton G.J., Nagy J.M., et al. The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976, 114(1):115-122.
31. Mohamed Hoesein F.A., Zanen P., Lammers J.W. Lower limit of normal or FEV1/FVC < 0.70 in diagnosing COPD: an evidence-based review. Respir Med 2011, 105(6):907-915.
32. Glaab T., Vogelmeier C., Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res 2010, 11:79.
33. Sethi S., Evans N., Grant B.J., et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002, 347(7):465-471.
34. Wu J., Sin D.D. Improved patient outcome with smoking cessation: when is it too late?. Int J Chron Obstruct Pulmon Dis 2011, 6:259-267.
35. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011, 2. CD006103.
36. Ries A.L., Bauldoff G.S., Carlin B.W., et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131(Suppl 5):4S-42S.
37. Rice K.L., Dewan N., Bloomfield H.E., et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2010, 182(7):890-896.
38. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981, 1(8222):681-686.
39. Anthonisen N.R. Long-term oxygen therapy. Ann Intern Med 1983, 99(4):519-527.
40. Qaseem A., Wilt T.J., Weinberger S.E., et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011, 155(3):179-191.
41. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
42. Wise R.A., Tashkin D.P. Optimizing treatment of chronic obstructive pulmonary disease: an assessment of current therapies. Am J Med 2007, 120(8 Suppl 1):S4-S13.
43. Sin D.D., McAlister F.A., Man S.F., et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003, 290(17):2301-2312.
44. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006, 129(1):15-26.
45. Salpeter S.R., Ormiston T.M., Salpeter E.E. Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma. Ann Intern Med 2004, 140(10):802-813.
46. Tashkin D.P., Celli B., Senn S., et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15):1543-1554.
47. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 2008, 300(12):1439-1450.
48. Dorinsky P.M., Reisner C., Ferguson G.T., et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999, 115(4):966-971.
49. van Noord J.A., Aumann J.L., Janssens E., et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26(2):214-222.
50. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002, 113(1):59-65.
51. Hanania N.A., Darken P., Horstman D., et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003, 124(3):834-843.
52. Tashkin D.P. Budesonide and formoterol in a single pressurized metered-dose inhaler for treatment of COPD. Expert Rev Respir Med 2010, 4(6):703-714.
53. Rennard S.I., Tashkin D.P., McElhattan J., et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009, 69(5):549-565.
54. Tashkin D.P., Rennard S.I., Martin P., et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008, 68(14):1975-2000.
55. Ferguson G.T., Anzueto A., Fei R., et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med 2008, 102(8):1099-1108.
56. Calverley P.M., Anderson J.A., Celli B., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
57. Wedzicha J.A., Calverley P.M., Seemungal T.A., et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008, 177(1):19-26.
58. Ernst P., Gonzalez A.V., Brassard P., et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007, 176(2):162-166.
59. Calverley P.M., Stockley R.A., Seemungal T.A., et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011, 139(3):505-512.
60. Sin D.D., Tashkin D., Zhang X., et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009, 374(9691):712-719.
61. Aaron S.D., Vandemheen K.L., Fergusson D., et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8):545-555.
62. Singh D., Brooks J., Hagan G., et al. Superiority of " triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008, 63(7):592-598.
63. Gaebel K., McIvor R.A., Xie F., et al. Triple therapy for the management of COPD: a review. COPD 2011, 8(3):206-243.
64. Ford P.A., Durham A.L., Russell R.E., et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010, 137(6):1338-1344.
65. To Y., Ito K., Kizawa Y., et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010, 182(7):897-904.
66. Rabe K.F., Hiemstra P.S. Theophylline for chronic obstructive pulmonary disease? Time to move on. Am J Respir Crit Care Med 2010, 182(7):868-869.
67. Ram F.S., Rodriguez-Roisin R., Granados-Navarrete A., et al. WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, 1. CD004403.
68. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365(9454):167-175.
69. Puhan M. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011, 8. ED000028.
70. O'Byrne P.M., Gauvreau G. Phosphodiesterase-4 inhibition in COPD. Lancet 2009, 374(9691):665-667.
71. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration 2011, 81(1):75-87.
72. Altenburg J., de Graaff C.S., van der Werf T.S., et al. Immunomodulatory effects of macrolide antibiotics-part 1: biological mechanisms. Respiration 2011, 81(1):67-74.
73. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 2004, 125(Suppl 2):41S-50S. [quiz: 51S].
74. Albert R. Chronic azithromycin decreases the frequency of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2011, 183:A6416.
75. Young R.P., Hopkins R., Eaton T.E. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009, 18(114):222-232.
76. Dobler C.C., Wong K.K., Marks G.B. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009, 9:32.
77. Mancini G.B., Etminan M., Zhang B., et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12):2554-2560.
78. Vestbo J., Tan L., Atkinson G., et al. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009, 33(5):1039-1044.
79. Holverda S., Rietema H., Bogaard H.J., et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008, 21(3):558-564.
80. Janssens W., Bouillon R., Claes B., et al. Vitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding gene. Thorax 2010, 65(3):215-220.
81. Janssens W., Lehouck A., Carremans C., et al. Vitamin D beyond bones in chronic obstructive pulmonary disease: time to act. Am J Respir Crit Care Med 2009, 179(8):630-636.
82. Janssens W., Mathieu C., Boonen S., et al. Vitamin D deficiency and chronic obstructive pulmonary disease: a vicious circle. Vitam Horm 2011, 86:379-399.
83. Black P.N., Scragg R. Relationship between serum 25-hydroxyvitamin d and pulmonary function in the third national health and nutrition examination survey. Chest 2005, 128(6):3792-3798.
84. Connors A.F., Dawson N.V., Thomas C., et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996, 154(4 Pt 1):959-967.
85. Sin D.D., Tu J.V. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(4):580-584.
86. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000, 117(5 Suppl 2):380S-385S.
87. Bakri F., Brauer A.L., Sethi S., et al. Systemic and mucosal antibody response to Moraxella catarrhalis after exacerbations of chronic obstructive pulmonary disease. J Infect Dis 2002, 185(5):632-640.
88. Abe Y., Murphy T.F., Sethi S., et al. Lymphocyte proliferative response to P6 of Haemophilus influenzae is associated with relative protection from exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002, 165(7):967-971.
89. Murphy T.F., Sethi S., Hill S.L., et al. Inflammatory markers in bacterial exacerbations of COPD. Am J Respir Crit Care Med 2002, 165(1):132.
90. Fishman A., Martinez F., Naunheim K., et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348(21):2059-2073.
91. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001, 345(15):1075-1083.
92. Patel N., DeCamp M., Criner G.J. Lung transplantation and lung volume reduction surgery versus transplantation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008, 5(4):447-453.
93. Sethi S. The role of antibiotics in acute exacerbations of chronic obstructive pulmonary disease. Curr Infect Dis Rep 2003, 5(1):9-15.
94. Ernst A., Anantham D. Bronchoscopic lung volume reduction. Pulm Med 2011, 2011:610802.